Robin Swartz
PresidentMs. Robin Swartz served as Chief Operating Officer at Voyager Therapeutics, Inc since February 07, 2022 until October 20, 2026 and served as its Principal Financial Officer & Treasurer since May 8, 2026 until October 20, 2026 and served as its Principal Financial & Accounting Officer since April 12, 2024 and was its Chief Business Officer from November 2024 to October 20, 2026 and is its President from October 20, 2026 and served as its Acting Chief Business Officer until November 2024. She served as a Senior Vice President of Business Operations at Voyager Therapeutics, Inc until February 07, 2022 and served its Senior Vice President of Portfolio Management and Patient Engagement since 2021. She has experience across the industry; most recently, as Vice President, Patient and Product Services for Rare Diseases at Genzyme. She also served on the Sanofi-Aventis US LLC board of directors and was a member of the Executive Leadership. Ms. Swartz joined Voyager Therapeutics, Inc in 2021. She was responsible for the U.S. strategy and implementation of patient support and education, customer service and commercial operations for seven brands and two launch programs. During her time at Sanofi Genzyme, Robin also held leadership positions as Vice President, Head of Global and US Business Operations, Chief of Staff to the Executive Vice President and Senior Director, Finance. She served on the Sanofi Aventis Board of Directors, providing oversight to the US compliance program and was a member of the Executive Community Relations. Ms. Swartz received a B.A. in Political Science and Government from Kenyon College.
Positions
- Company NameVoyager Therapeutics, Inc.Stock CodeVYGRPositionPresidentColleagues
